Loading this company
Sarepta Therapeutics, Inc.
SRPTPrices in USD
TickerWorth ScoreC52/100
What we think
We do not publish a fair value for this company. The grade still applies.
Price
$17.44USD up +$0.33 (+1.96%)
Quoted · Prices are delayed.
Why did it move today?
Nothing we can cite explains today’s move for this company.
We do not put a fair value on this one
Our cash-flow model doesn't produce a meaningful value for this business — its projected free cash flow is so far from supporting the current price that the result is effectively zero, which tells you about the limits of the model on a fast-growing or loss-making company, not about what the business is worth. Here is what we can show instead.
Is it a good business?
- Valuation100 out of 100
- Growth0 out of 100
- Financial health83 out of 100
- Past performance0 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$21.64 across 22 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 835 people.
Key stats
52-week range$14.68–$24.68
- Open
- $17.25
- Day high
- $17.83
- Day low
- $17.12
- Previous close
- $17.10
- Volume
- 508,443 · 0.16× avg
- Average volume
- 3,087,096
- Market cap
- $1,841,607,168.00
- P/E (TTM)
- —
- Earnings per share
- −$1.57
- Beta
- 0.38
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Signed a material agreement
- Reported quarterly or annual results
- Changed leadership or its board
- Changed leadership or its board
- Reported quarterly or annual results
- Changed leadership or its board
- Reported quarterly or annual results
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Wong Ryan Ho-YanShares withheld (tax) · $294,903.84
- Estepan Ian MichaelShares withheld (tax) ·
Not investment advice. TickerWorth Score is a model output.